This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Biotinylated Human Mesothelin / MSLN (296-580), Fc Tag, ultra sensitivity (primary amine labeling) (MALS verified)
catalog :
MSN-H826x
quantity :
25 ug, 200 ug
price :
290 USD, 1250 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
MSN-H826x
product name :
Biotinylated Human Mesothelin / MSLN (296-580), Fc Tag, ultra sensitivity (primary amine labeling) (MALS verified)
quantity :
25 ug, 200 ug
price :
290 USD, 1250 USD
quantity & price :
$290/25ug,$1250/200ug
target :
Mesothelin
host species :
Human
By Tag :
Fc Tag
Research :
For Research Use Only
Source :
MABSol® Biotinylated Human Mesothelin (296-580), Fc Tag (MSN-H826x) is expressed from human HEK293 cells. It contains AA Glu 296 - Gly 580 (Accession # AAH09272). It is the biotinylated form of Human Mesothelin (296-580), Fc Tag (MSN-H526x).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Biotinylated Human Mesothelin, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Mesothelin (MSLN) is also known as CAK1 antigen, Pre-pro-megakaryocyte-potentiating factor, which belongs to the mesothelin family. Mesothelin / MSLN can be proteolytically cleaved into the following two chains by a furin-like convertase: Megakaryocyte-potentiating factor (MPF) and the cleaved form of mesothelin. Both MPF and the cleaved form of mesothelin are N-glycosylated. Mesothelin / MSLN can interacts with MUC16. The membrane-anchored forms of MSLN may play a role in cellular adhesion. MPF potentiates megakaryocyte colony formation in vitro.
References :
(1) Chang K., et al., 1996, Proc. Natl. Acad. Sci. U.S.A. 93:136-140.
(2) Yamaguchi N., et al., 1994, J. Biol. Chem. 269:805-808.
(3) Rump A., et al., 2004, J. Biol. Chem. 279:9190-9198.
(4) Ma J., et al., 2012, J. Biol. Chem. 287:33123-33131.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments